X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7915) 7915
Publication (952) 952
Book Review (65) 65
Book Chapter (53) 53
Conference Proceeding (20) 20
Dissertation (18) 18
Data Set (1) 1
Magazine Article (1) 1
Paper (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sorafenib (7496) 7496
index medicus (4523) 4523
humans (4377) 4377
oncology (3334) 3334
hepatocellular carcinoma (2400) 2400
cancer (2373) 2373
male (2231) 2231
female (2092) 2092
niacinamide - analogs & derivatives (2090) 2090
middle aged (1787) 1787
aged (1573) 1573
sunitinib (1511) 1511
antineoplastic agents - therapeutic use (1391) 1391
treatment outcome (1249) 1249
survival (1161) 1161
adult (1143) 1143
liver cancer (1112) 1112
care and treatment (1077) 1077
liver neoplasms - drug therapy (1038) 1038
carcinoma, hepatocellular - drug therapy (991) 991
metastasis (966) 966
animals (909) 909
therapy (890) 890
hepatoma (887) 887
liver neoplasms - pathology (884) 884
carcinoma, renal cell - drug therapy (880) 880
chemotherapy (865) 865
kidney neoplasms - drug therapy (852) 852
phenylurea compounds (820) 820
carcinoma, hepatocellular - pathology (819) 819
antineoplastic agents (803) 803
prognosis (799) 799
angiogenesis (777) 777
antimitotic agents (769) 769
pharmacology & pharmacy (761) 761
apoptosis (745) 745
renal cell carcinoma (737) 737
analysis (731) 731
efficacy (723) 723
tumors (723) 723
cell line, tumor (694) 694
interferon-alpha (687) 687
digestive system diseases (685) 685
gastroenterology & hepatology (678) 678
aged, 80 and over (672) 672
bevacizumab (672) 672
phenylurea compounds - therapeutic use (654) 654
protein kinase inhibitors - therapeutic use (640) 640
expression (639) 639
medicine & public health (621) 621
retrospective studies (620) 620
antineoplastic agents - pharmacology (615) 615
antineoplastic agents - adverse effects (607) 607
drug therapy (602) 602
niacinamide - therapeutic use (602) 602
carcinoma (563) 563
disease-free survival (554) 554
kidney neoplasms - pathology (551) 551
double-blind (549) 549
trial (547) 547
neoplasms (539) 539
research (538) 538
mice (533) 533
endothelial growth-factor (528) 528
vascular endothelial growth factor (525) 525
carcinoma, renal cell (524) 524
cancer therapies (494) 494
targeted therapy (494) 494
pyridines - therapeutic use (483) 483
renal-cell carcinoma (472) 472
phase-ii (466) 466
kinases (460) 460
management (459) 459
antineoplastic agents - administration & dosage (448) 448
patients (446) 446
phenylurea compounds - administration & dosage (444) 444
antineoplastic combined chemotherapy protocols - therapeutic use (443) 443
liver (442) 442
transarterial chemoembolization (438) 438
medical prognosis (437) 437
safety (434) 434
health aspects (430) 430
benzenesulfonates - therapeutic use (423) 423
niacinamide - administration & dosage (422) 422
hepatocellular-carcinoma (415) 415
phenylurea compounds - pharmacology (411) 411
article (410) 410
tyrosine kinase inhibitor (410) 410
everolimus (406) 406
cell proliferation - drug effects (404) 404
neoplasm staging (399) 399
combination (392) 392
urology & nephrology (387) 387
niacinamide - pharmacology (385) 385
carcinoma, renal cell - pathology (384) 384
phase-ii trial (384) 384
cell biology (383) 383
clinical trials (383) 383
liver neoplasms - therapy (376) 376
carcinoma, hepatocellular - therapy (375) 375
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7359) 7359
Korean (175) 175
German (137) 137
French (118) 118
Japanese (76) 76
Spanish (39) 39
Chinese (25) 25
Russian (20) 20
Polish (12) 12
Czech (8) 8
Italian (5) 5
Portuguese (3) 3
Turkish (3) 3
Hungarian (2) 2
Slovak (2) 2
Catalan (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Therapeutic Research, ISSN 0289-8020, 2015, Volume 36, Issue 4, pp. 371 - 375
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 06/2019, Volume 17, Issue 6, pp. 758 - 760
Journal Article
by Qi, XS and Jia, J and Fan, DM and Han, GH
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 03/2014, Volume 32, Issue 9, pp. 968 - 968
Journal Article
World Journal of Gastroenterology, ISSN 1007-9327, 09/2018, Volume 24, Issue 36, pp. 4152 - 4163
Journal Article
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, ISSN 1759-5045, 03/2017, Volume 14, Issue 3, pp. 141 - 142
Drug development in hepatocellular carcinoma had essentially stalled since 2008 when sorafenib was established as the modest standard of care. Now, a positive... 
SORAFENIB | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 1737, Volume 111, Issue 14, pp. 5319 - 5324
Journal Article
Molecules, ISSN 1420-3049, 2018, Volume 23, Issue 1, p. 24
Both EGFR and VEGFR-2 play a critical role in tumor growth, angiogenesis and metastasis, and targeting EGFR and VEGFR-2 simultaneously represents a promising... 
Thiourea | Quinazoline | Sorafenib | Molecular docking | TK inhibitor | ANTITUMOR AGENTS | quinazoline | thiourea | molecular docking | sorafenib | BIOCHEMISTRY & MOLECULAR BIOLOGY | GROWTH | BIOLOGICAL-ACTIVITIES | DERIVATIVES | CHEMISTRY, MULTIDISCIPLINARY | Quinazolines - chemical synthesis | Thiourea - therapeutic use | Antineoplastic Agents - chemical synthesis | Humans | Melanoma, Experimental - drug therapy | Antineoplastic Agents - therapeutic use | Thiourea - pharmacology | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Thiourea - chemical synthesis | Drug Design | Antineoplastic Agents - pharmacology | Cell Survival - drug effects | Molecular Docking Simulation - methods | ErbB Receptors - antagonists & inhibitors | Mice, Inbred C57BL | Sorafenib - chemical synthesis | Sorafenib - analogs & derivatives | Sorafenib - pharmacology | Sorafenib - therapeutic use | Xenograft Model Antitumor Assays | Animals | Quinazolines - therapeutic use | Cell Line, Tumor | Protein Binding | Cell Proliferation - drug effects | Quinazolines - pharmacology | Biotechnology | Model testing | Epidermal growth factor receptors | Melanoma | Thioureas | Kinases | Vascular endothelial growth factor receptors | Anticancer properties | Metastases | Analogs | Angiogenesis | Inhibitors | Antitumor agents | Cell lines | Xenografts | In vivo methods and tests | Cancer
Journal Article
JDDG - Journal of the German Society of Dermatology, ISSN 1610-0379, 12/2018, Volume 16, Issue 12, pp. 1486 - 1489
Journal Article
Journal Article
Journal Article
Acta Biomaterialia, ISSN 1742-7061, 05/2018, Volume 72, pp. 248 - 255
Proposed mechanism of miR-375/Sf-LCC NPs for anti-tumor effects and autophagy inhibition in HCC. Sorafenib is a first-line drug for hepatocellular carcinoma... 
microRNA | Hepatocellular carcinoma | Nanoparticle | Nanomedicine | Autophagy | Cancer | DRUG | CELLS | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | TUMOR | SORAFENIB | CHLOROQUINE | MULTIKINASE INHIBITOR | CHEMOTHERAPY | DELIVERY | BREAST-CANCER | MIR-375 | Nanoparticles - chemistry | Humans | Coated Materials, Biocompatible - pharmacology | Delayed-Action Preparations - chemistry | MicroRNAs - pharmacokinetics | Sorafenib - chemistry | MicroRNAs - pharmacology | Calcium Carbonate - chemistry | Lipids - chemistry | Carcinoma, Hepatocellular - drug therapy | Lipids - pharmacology | Nanoparticles - therapeutic use | Delayed-Action Preparations - pharmacology | Delayed-Action Preparations - pharmacokinetics | Liver Neoplasms - pathology | Calcium Carbonate - pharmacokinetics | Coated Materials, Biocompatible - pharmacokinetics | Sorafenib - pharmacokinetics | Liver Neoplasms - drug therapy | Coated Materials, Biocompatible - chemistry | Sorafenib - pharmacology | Hep G2 Cells | Xenograft Model Antitumor Assays | Animals | Lipids - pharmacokinetics | Mice, Nude | Carcinoma, Hepatocellular - pathology | Liver Neoplasms - metabolism | Mice | Calcium Carbonate - pharmacology | MicroRNAs - chemistry | Carcinoma, Hepatocellular - metabolism | Antimitotic agents | Nanoparticles | Pharmacy | Analysis | Calcium carbonate | Drugstores | Hepatoma | Antineoplastic agents
Journal Article
08/2011
Background: The relationship of epidermal growth factor receptors (EGFR) pathway, such as PI3K, K-ras, and B-raf, with response to EGFR-targeted antibodies is... 
sorafenib | metastatic colorectal carcinoma | K-ras | cetuximab
Web Resource
CANCER RESEARCH, ISSN 0008-5472, 09/2019, Volume 79, Issue 17, pp. 4326 - 4330
Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six... 
DOUBLE-BLIND | PHASE-3 | ONCOLOGY | SORAFENIB
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 2018, Volume 41, Issue 3, pp. 147 - 147
Journal Article
Acta Biomaterialia, ISSN 1742-7061, 07/2018, Volume 75, pp. 413 - 426
Journal Article
Cancer, ISSN 0008-543X, 02/2011, Volume 117, Issue 3, pp. 534 - 544
BACKGROUND: Sunitinib and sorafenib are tyrosine kinase inhibitors that have important antitumor activity in metastatic renal cell carcinoma (mRCC).... 
sunitinib | renal cell carcinoma | sorafenib | hypothyroidism | predictive factors
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.